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)is is a case of Actinomyces europaeus in the breast abscess of a penicillin-allergic woman. )e mainstay of treatment for
actinomycosis is penicillin, and there is a lack of literature describing nonpenicillin treatment options. A 69-year-old woman
presented acutely with a breast abscess which was managed with incision and drainage and antibiotic therapy to good response. 21
days after presentation, Actinomyces were grown from the culture of pus, so the patient was recalled and more rigorous treatment
and follow-up were initiated. )e penicillin allergy led to diﬃculty in the identiﬁcation of an appropriate antimicrobial agent that
was also logistically feasible to be given on an outpatient IV basis. IV tigecycline followed by oral clarithromycin was found to be
eﬀective treatment.
1. Introduction
Actinomyces species are normal commensal bacteria that can
be found in the oral cavity and the lower reproductive tract of
women [1]. )e bacteria are Gram-positive, ﬁlamentous, non-
acid-fast, and anaerobic-to-microaerophilic [2]. )is species is
pathogenic but nonvirulent, so infection is often opportunistic
leading to actinomycosis which is a rare subacute-to-chronic
infection [3]. Actinomycosis is characterised by localised
spread via abscess and sinus tracts with granulomatous in-
ﬂammation [2]. Due to this propensity for local spread,
identiﬁed infections should be investigated for deep sources
which may contribute to an ongoing insidious clinical source
or may be mistaken for other pathologies such as carcinomas
[4]. Diagnosis of actinomycosis is mainly by examination of
microbiological samples because clinical suspicion is low and
clinicians are unfamiliar with the presentation [5].
)e commonest locations of classic actinomycosis infection
are cervicofacial, thoracic, abdominal, and pelvic.A. israelii and
A. gerencseriae are the causative agents in 70% of infections [6];
however, A. europaeus is a much more rare species most often
associated with skin and soft tissue infections [7, 8]. A.
europaeus can display intrinsic resistance to many antibiotics
including ciproﬂoxacin, erythromycin, and linezolid, as well as
reduced susceptibility to piperacillin/tazobactam [9]. )is is an
additional diﬃculty in the treatment ofA. europaeus and limits
the nonpenicillin-based antimicrobial options.
Breast abscesses caused by A. europaeus are very rare but
have been described in the literature. )is case is novel in
that the patient is penicillin allergic, therefore making
suitable outpatient parenteral antibiotic therapy (OPAT)
choices extremely diﬃcult.
2. Case Report
A 69-year-old lady with a background of penicillin allergy
and left-sided breast cancer treated with mastectomy and
axillary node clearance was admitted to the hospital in
Liverpool in 2016 with a right-sided breast abscess. )e
patient had been aware of a lump in her right breast for 3
years and had been told it was a sebaceous cyst. However, it
had become painful, and she was now feeling unwell and
tachycardic but remained apyrexial.
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Antibiotic therapy was initiated with IV clindamycin
450mg TDS and IV teicoplanin 12mg/kg BD and then with
12mg/kg OD after 2 days. )e abscess was aspirated and
subsequently incised and drained under local anaesthetic.
)e frank pus drained was malodorous, so oral metroni-
dazole 500mg TDS was added on. As there was no clinical
improvement after 48 hours, a second incision and drainage
was performed under general anaesthetic, revealing a large
abscess cavity extending 10 cm into the right breast and 7 cm
into the left mastectomy scar.)is combined with continued
triple antibiotic therapy resulted in clinical improvement, so
after 4 days of IV therapy, antibiotics were stepped down to
oral erythromycin 500mg QDS of 7-day course and met-
ronidazole 500mg TDS of 10-day course and the patient was
discharged. )e abscess healed well in the community.
Twenty-one days after sending aspirated pus for MC+ S,
Actinomyces europaeuswas grown in the culture.)e patient
was still clinically well, the abscess was healing well, and no
underlying chest source of infection was identiﬁed.
)e breast abscess pus was sent to the microbiology
laboratory for testing. )ere were Gram-positive cocci
visualised on the direct Gram stain, but there was no evidence
of any Gram-positive bacilli. )e pus was cultured onto the
following plates: blood agar, MacConkey agar, selective an-
aerobic agar with a 5-microgram disc, and a fastidious an-
aerobic agar (FAA) plate in accordance with the laboratory
standard operating procedure (SOP) based on the UK Stan-
dards for Microbiology Investigations (SMI) [10]. After 4 days
of growth, two colonies grew on the direct FAA plate, which
were diﬀerent. )e ﬁrst colony was identiﬁed, using a matrix-
assisted laser desorption/ionisation (MALDI-TOF) machine,
as a Staphylococcus epidermidis. )e MALDI-TOF equipment
used was Bruker Microﬂex utilising MALDI Biotyper Version
3.1 software. )e MS method of identiﬁcation was the AutoX
setting, and the software library was the BDAL and Fila-
mentous Fungi Library Version 1.0. )e second colony failed
to be identiﬁed usingMALDI.)erefore, the second organism
was subbed onto an Actinomyces plate (blood agar with
supplementary metronidazole and nalidoxic acid) in accor-
dance with the local SOP. Four days later, there was ﬁne
growth on the Actinomyces plate. Sensitivities were obtained
via the British Society for Antimicrobial Chemotherapy
(BSAC) method of disc diﬀusion. )e organism was sensi-
tive to penicillin 42mm (sensitivity> 23mm), erythromycin
40mm (sensitivity> 10mm), vancomycin 30mm (no break-
point available), tetracycline 42mm (no breakpoint available),
and ciproﬂoxacin 22mm (no breakpoint available). )e or-
ganism was initially identiﬁed as Actinomyces europaeus, but
the MALDI score was only 1.82; therefore, an extraction
MALDI was performed to increase the MALDI score, so
a more conﬁdent identiﬁcation of the organism was obtained.
)e subsequent MALDI identity was Actinomyces europaeus
with a score of 2.10. As per the guidance from the SMI, the
organismwas sloped and sent to the Anaerobic Reference Unit
at Colindale. )e ID was conﬁrmed as Actinomyces europaeus
by partial sequencing of 16sRNA.
Microbiological advice consisted of a long course of
antibiotics to eradicate the infection, and the ﬁrst-line
treatment was 2 weeks of IV ceftriaxone followed by 6
months of oral amoxicillin. )is was not feasible due to the
patient’s penicillin allergy.
Second-line advice was 2 weeks of IV erythromycin
followed by 6 months of oral erythromycin. However, this
was also not feasible. )e outpatient parenteral antibiotic
therapy (OPAT) service enables patients to receive IV
therapy in the community but was unable to provide the four
times daily dosing required for IV erythromycin. )e OPAT
service was only able to provide twice daily regimens.
)e third-line approach was acceptable: 2 weeks of IV
tigecycline given in twice daily doses followed by 6 months of
oral doxycycline. )e patient had a midline inserted and re-
ceived her IV therapy in the community with OPAT services.
After completing the IV tigecycline course with no is-
sues, the patient complained of side eﬀects following 6 weeks
of oral doxycycline therapy: oral thrush and leg blisters.
Antibiotic therapy was switched to oral clarithromycin to
complete a 6-month course of oral antibiotics. )ere has
been no evidence of recurrence to date.
3. Discussion
)is case is novel because the patient involved is allergic to
penicillin. )e case was further complicated by the need to
design a parenteral antimicrobial regimen that was logisti-
cally feasible to deliver on an outpatient basis.
)e Actinomyces species are generally sensitive to pen-
icillin, so this is recommended as the ﬁrst-line therapy.
Consideration may also be given to concomitant bacteria
that may be resistant to penicillins and continue the in-
ﬂammation after the actinomycetes have been treated; for
example, dual therapy may be utilised with metronidazole
for anaerobic cover in addition to penicillin [11]. Prolonged
antibiotic courses are required (typically 6 months) in order
for the treatment to penetrate abscesses and infected tissue
[6]. However, combined surgical-medical treatment such as
resection of infected tissue followed by antimicrobial ther-
apy may shorten the required antimicrobial therapy dura-
tion [6]. )erapy duration of less than 3 months is not
recommended due to the high risk of recurrence [12].
Treatment of all forms of actinomycosis traditionally in-
volves high-dose IV penicillin G for two to six weeks of
duration, followed by a step down to oral penicillin V for
6–12 months [3, 13]. Prolonged courses of parenteral an-
tibiotics can be challenging to provide as they require
specialist administration. Outpatient parenteral antibiotic
therapy (OPAT) services can facilitate this.
OPATwas initially developed in the US in the 1970s for
the management of children with cystic ﬁbrosis [14], and it
has since been extrapolated to treat many conditions
worldwide. Outpatient therapy avoids the costs associated
with inpatient admission and freeing up more inpatient beds
while reducing the risk of hospital-associated infections [15]
and improving the quality of life by allowing the patient to
remain at home.
Care must be taken to ensure that the patient is suitable
for outpatient management as the condition must be stable
with low risk of deterioration [16]. )e patient in question
fulﬁlled this criterion because she had been managing her
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condition in the community for 2 weeks prior to being
recalled to hospital and she had a good family support
network to help her if required.
OPATservices can be delivered in 3 ways: at an outpatient
clinic, by a health care professional at the patient’s home, or
self-administration by the patient. Self-administration enables
more ﬂexibility in dose frequency; however, the patient in
question was frail with comorbidities that made this option
diﬃcult. Funding and capacity of OPAT services exclude the
ability to provide therapies that require frequent dosing either
by staﬀ at home or in a clinic—this factor rendered eryth-
romycin inappropriate as an outpatient therapy option.
)ere is much conﬂict in the literature regarding
A. europaeus sensitivities and resistance. A. europaeus is
widely reported as the species of Actinomyces that has the
highest resistance rates [9, 17, 18], and some in vitro studies
have described evidence of resistance or reduced suscepti-
bility ofA. europaeus to erythromycin [9, 17], whereas others
have described erythromycin to be the most active anti-
microbial agent in the treatment of A. europaeus [9]. Good
sensitivity to erythromycin was demonstrated in this isolate.
)is could be the impact of evolving antibiotic resistance
secondary to antimicrobial misuse and overuse, and espe-
cially macrolide resistance is being increasingly reported in
skin and soft tissue infections [19]. However, erythromycin
is recommended as a nonpenicillin antibiotic therapy for
treatment of Actinomyces infection [3, 20], and tetracyclines
have also been recommended [9]. )e use of tetracyclines
highlights the importance of correctly identifying the Ac-
tinomyces species asA. europaeus is generally sensitive, while
other species display resistance to tetracyclines [20].
4. Conclusion
)is report considers the diﬃculty in identifying a clinically
viable antimicrobial agent for the treatment of A. europaeus
that is also logistically feasible as an outpatient parenteral
therapy. )is concern may become more prevalent as the
push in NHS management is towards care based in the
community rather than hospitals. )is will help to reduce
the hospital-associated morbidity such as infections and ease
the pressures on bed availability.
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